Study of Acalabrutinib in Chinese Adult Subjects with Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or other B-cell Malignancies

Trial Identifier:	D8220C00007
Sponsor:	AstraZeneca
NCTID::	NCT03932331
Start Date:	April 2020
Primary Completion Date:	June 2022
Study Completion Date:	December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	beijing, CN, 100191
CN	Beijing, CN, 100044
CN	Beijing, CN, 100142
CN	Changchun, CN, 130021
CN	Changsha, CN, 410008
CN	changzhou, CN, 272100
CN	Chengdu, CN, 610041
CN	fuzhou, CN
CN	Haikou, CN, 570311
CN	Hangzhou, CN, 310022
CN	Hangzhou, CN, 310003
CN	Harbin, CN, 150049
CN	Hefei, CN, 230031
CN	Hohhot, CN, 10050
CN	Nanchang, CN, 330006
CN	Nanjing, CN, 210029
CN	Shanghai, CN, 200032
CN	suzhou, CN, 215006
CN	tianjin, CN, 300020
CN	Tianjin, CN, 300060
CN	Urumqi, CN, 830054
CN	Xining, CN, 810007
CN	Zhengzhou, CN, 450008

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company